Skip to main content

Foley Todd's Form 4 filing

Aktis Oncology, Inc.AKTS · filed Jan 14, 2026

Accession no.
0001473930-26-000005
Filed
Jan 14, 2026
Trade date
Jan 12, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $4.19M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Foley ToddCIK 0001473930Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 12, 2026Common StockCConversionAcquired+597,391–F2–597,391Indirect
Jan 12, 2026Common StockCConversionAcquired+2,688,270–F2–3,285,661Indirect
Jan 12, 2026Common StockCConversionAcquired+716,872–F2–4,002,533Indirect
Jan 12, 2026Common StockPPurchaseAcquired+232,870$18.00+$4,191,6604,235,403Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 12, 2026Common StockCConversionDisposed−597,391$0.00F2$00Indirect
Jan 12, 2026Common StockCConversionDisposed−2,688,270$0.00F2$00Indirect
Jan 12, 2026Common StockCConversionDisposed−716,872$0.00F2$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.

Referenced by the price of 3 transactions in Table I and 3 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)